NovAccess Global Inc. (XSNX)
| Market Cap | 12.33K -33.3% |
| Revenue (ttm) | n/a |
| Net Income | -2.66M |
| EPS | -0.06 |
| Shares Out | 61.65M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 55,100 |
| Open | 0.0002 |
| Previous Close | 0.0002 |
| Day's Range | 0.0002 - 0.0002 |
| 52-Week Range | 0.0001 - 0.0500 |
| Beta | 98.88 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 26, 2026 |
About NovAccess Global
NovAccess Global Inc., a biopharmaceutical company, engages in the development of novel immunotherapies to treat brain tumor patients in the United States. It specializes in cutting-edge research related to utilizing a patient's immune system to attack the cancer. NovAccess Global Inc. was incorporated in 1997 and is headquartered in New York, New York. [Read more]
Financial Performance
Financial StatementsNews
NovAccess Global files patent with Cedars-Sinai
NovAccess Global has submitted a provisional patent for new intellectual property developed at Cedars-Sinai to advance the Company’s immunotherapy platform. The patent pertains to the use of a specifi...
NovAccess Global Advisory on Annual Meeting of Shareholders
CLEVELAND, OH / ACCESSWIRE / May 7, 2024 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced the postponement of its A...
NovAccess Global announces license to advance immunotherapy platform
NovAccess Global announced the procurement of a new intellectual property license from Cedars-Sinai Medical Center to further advance the Company’s immunotherapy platform. The license pertains to the ...
NovAccess Global Announces New License to Advance its Immunotherapy Platform
CLEVELAND, OH / ACCESSWIRE / April 30, 2024 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing a novel immunotherapy for patients suffering from cancers of the central nervous syste...
NovAccess Global says financing transaction with Sumner remains pending
NovAccess Global provided an update on business developments, financing and the 2024 annual meeting. The previously disclosed $10.7 million financing transaction with Sumner Global LLC remains pending...
NovAccess Global Provides Business Updates and Announces Scheduling of Annual Meeting of Shareholders
CLEVELAND, OH / ACCESSWIRE / March 1, 2024 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today provided an update on business de...
NovAccess Global announces $10.7M financing
NovAccess Global entered into a securities purchase agreement with an affiliate of Sumner Global for a total financing of $10.7M. Pursuant to the agreement, Sumner agreed to purchase 33M newly…
NovAccess Global Announces $10.7 Million Financing
Establishes Strong Financial Base To Advance Development of Novel Cancer Immunotherapies CLEVELAND, OH / ACCESSWIRE / January 2, 2024 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company develop...
NovAccess Global Inc. to Present at the December 7th Virtual Investor Summit
Cleveland, Ohio--(Newsfile Corp. - December 1, 2023) - NovAccess Global Inc. (OTCQB: XSNX) announced today it will be presenting at the December 7th, 2023 virtual Investor Summit. Event: December 7th ...
NovAccess Global appoints Roscoe Moore to scientific advisory board
NovAccess Global announced the appointment of Dr. Roscoe M. Moore, Jr., to its Scientific Advisory Board. Dr. Moore was a career officer within the Commissioned Corps of the United States…
NovAccess Global Appoints Dr. Roscoe M. Moore, Jr. to Scientific Advisory Board
CLEVELAND, OH / ACCESSWIRE / November 10, 2023 / NovAccess Global Inc. (OTCQB:XSNX), a preclinical biomedical company developing novel immunotherapies for brain tumor patients, today announced the app...
NovAccess Global, BCN Biosciences partner for immunotherapy platform
NovAccess Global announced the signing of a Letter of Intent and formation of a partnership with BCN Biosciences to expand its immunotherapy platform. Utilizing BCN’s small molecule drug BCN057, devel...
NovAccess Global Partners with BCN Biosciences to Expand Immunotherapy Platform
Development Begins on Fourth Generation of Primary Drug TLR-AD1 Targeting CNS Tumors Potential for Improved Outcomes for Cancer Patients in the $100 Billion a Year Immune Oncology Market CLEVELAND, OH...
NovAccess Global to Participate in National Brain Tumor Society's Annual Glioblastoma Awareness Day
CLEVELAND, OH / ACCESSWIRE / July 13, 2023 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced that its Chief Executiv...
NovAccess Global Partners with CKN Ventures to Expand its New AI-driven Precision Medicine Division
CLEVELAND, OH and BANGKOK, THAILAND / ACCESSWIRE / June 16, 2023 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced a...
NovAccess Global Launches Precision Medicine Division Using AI, Big Data and Predictive Technologies to Accelerate Personalized Healthcare Therapies
CLEVLAND, OH / ACCESSWIRE / June 1, 2023 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced the formation of its Prec...
NovAccess Global Lead Scientist Published in High-Profile Medical Journal for Cancer Vaccine Advancements
Report Details Promise of Adaptive Cancer Immunotherapy in Treating Highly Malignant Brain Tumors Recent Achievements for Glioblastoma/Brain Tumor Treatment to be Addressed in Upcoming Presentation at...
Dr. Christopher Wheeler, NovAccess Lead Scientist, Receives Prestigious Golden Axon Award
Dr. Christopher Wheeler, NovAccess Lead Scientist, Receives Prestigious Golden Axon Award CLEVELAND, OH / ACCESSWIRE / March 15, 2023 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company develop...
NovAccess Global CEO to present at World Orphan Drug Congress
NovAccess Global announced that its CEO Dr. Dwain Irvin has been invited to present at the World Orphan Drug Congress, scheduled for May 23-25, 2023, near Washington, DC. Dr. Christopher…
NovAccess Global to Present at World Orphan Drug Congress
CLEVELAND, OH / ACCESSWIRE / February 16, 2023 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced that its CEO Dr. Dw...
NovAccess Global Leadership to Present at World Brain Mapping Foundation Annual Congress
Dr. Christopher Wheeler, NovAccess Lead Scientist, to Receive Leadership Award for his Contributions CLEVELAND, OH / ACCESSWIRE / February 3, 2023 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical co...
NovAccess Global Announces Fireside Chat with Dr. Christopher Wheeler, the Company's Lead Scientist and President of its StemVax Therapeutics Division
Topic: Immunotherapy Advantages Over Surgical Treatment CLEVELAND, OH / ACCESSWIRE / January 5, 2023 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for bra...
NovAccess Global Announces Initial Fireside Chat with Glioblastoma Patient Advocate
Topic: Benefits of Immunotherapies Versus Conventional Chemotherapy for Patients and Their Support Networks CLEVELAND, OH / ACCESSWIRE / November 22, 2022 / NovAccess Global Inc. (OTCQB:XSNX), a biome...
NovAccess Global Appoints Healthcare IP Consultant Dr. Peter Weinstein to Scientific Advisory Board
CLEVELAND, OH / ACCESSWIRE / November 10, 2022 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced the appointment of ...
NovAccess Global Receives FDA Approval of Orphan Drug Application for TLR-AD1
NovAccess Global Receives FDA Approval of Orphan Drug Application for TLR-AD1 FDA Expands the Scope of the Company's Submission Accelerates Path Toward Immunotherapy for Glioblastoma (Brain Cancer) CL...